Can Spironolactone Cause Hematuria and Dysuria?
Spironolactone does not directly cause hematuria or dysuria as recognized adverse effects. The FDA drug label and major cardiovascular guidelines do not list hematuria (blood in urine) or dysuria (painful urination) among spironolactone's known side effects 1.
Documented Adverse Effects of Spironolactone
The FDA-approved labeling identifies the following adverse reactions for spironolactone 1:
- Renal effects: Renal dysfunction (including renal failure), hyperkalemia, electrolyte disturbances, hypovolemia
- Gastrointestinal: Gastric bleeding, ulceration, gastritis, diarrhea, cramping, nausea, vomiting
- Reproductive: Gynecomastia, breast pain, decreased libido, erectile dysfunction, menstrual irregularities
- Hematologic: Leukopenia, thrombocytopenia
- Hypersensitivity: Urticaria, rash, anaphylaxis, vasculitis
- Neurologic: Lethargy, confusion, ataxia, dizziness, headache
- Hepatic: Mixed cholestatic/hepatocellular toxicity (rare)
Notably absent from this comprehensive list are hematuria and dysuria 1.
Renal Dysfunction as an Indirect Mechanism
While spironolactone can cause renal dysfunction and acute kidney injury (AKI), particularly in patients with pre-existing kidney disease, this manifests primarily as 1, 2:
- Elevated serum creatinine
- Decreased estimated glomerular filtration rate (eGFR)
- Hyperkalemia
- Worsening renal function
The incidence of AKI with spironolactone use in heart failure patients is 10.1 events per 1000 person-months, with a 12% increased hazard compared to loop diuretics alone 2. However, even in these cases of drug-induced renal dysfunction, hematuria and dysuria are not reported as manifestations.
Critical Monitoring Parameters
If a patient on spironolactone develops hematuria or dysuria, alternative etiologies must be investigated 3, 4. The ESC guidelines emphasize monitoring for 3, 4:
- Hyperkalemia: Check potassium at 1 and 4 weeks after initiation, then at 1,2,3, and 6 months
- Worsening renal function: Monitor creatinine at the same intervals
- Discontinue if: Potassium >6.0 mEq/L or creatinine >310 µmol/L (3.5 mg/dL)
High-Risk Populations for Spironolactone-Related Renal Complications
Patients at increased risk for spironolactone-induced renal dysfunction (though not specifically hematuria/dysuria) include 5, 2:
- Age >70 years
- Baseline renal insufficiency (eGFR <60 mL/min)
- Diabetes mellitus
- Concurrent use of ACE inhibitors or ARBs
- Dehydration or volume depletion
- Doses >25 mg daily
In a case series of life-threatening hyperkalemia with combined ACE inhibitor and spironolactone therapy, the mean age was 74 years with baseline creatinine of 3.8 mg/dL, but urinary symptoms were not reported 5.
Clinical Recommendation
If hematuria or dysuria occurs in a patient taking spironolactone, pursue standard urologic evaluation including:
- Urinalysis with microscopy
- Urine culture
- Assessment for urinary tract infection, nephrolithiasis, malignancy, or glomerulonephritis
- Consider cystoscopy and imaging if indicated
Do not attribute these symptoms to spironolactone without excluding other causes, as they are not recognized adverse effects of this medication 1. The temporal association alone is insufficient to establish causality when well-documented side effects do not include these urinary symptoms.